The proposed research has the following specific goals: (1) to assess, at the clinical level, noradrenergic (NA), benzodiazepine-gammaminobutyric acid receptor (BZ-GABA), and serotonergic (5-HT) function in healthy subjects and patients with Agoraphobia and Panic Attacks (APA) to determine whether there is a dysfunction of these systems in APA. (2) Examination of the antipanic efficacy of lorazepam and [buspirone] compared to placebo and imipramine in a double blind treatment protocol. The effectiveness of these treatments will be analyzed in relation to pretreatment clinical variables, especially the severity of depression and agoraphobia, the frequency of panic attacks and the neurobiological profile. Particular attention will be directed toward the time course of treatment efficacy and the spectrum of symptoms affected. (3) Investigation of the mechanism of action of drugs effective in the treatment of APA. This will be done by determination of the effects of lorazepam, [buspirone], imipramine and placebo on NA, BZ-GABA and 5-HT function over whether such effects are related to treatment response. Norepinephrine turnover will be measured by determination of plasma free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) levels. The effects of the alpha-2 adrenergic autoreceptor antagonist, yohimbine, on MHPG, cortisol, ACTH, behavior, cardiovascular function, and somatic symptoms will be used as an index of NA function. BZ-GABA receptor function will be assessed by determining the biochemical, behavioral and autonomic effects of pentylenetetrazol, a competitive antagonist of [3H]-diazepam binding. Serotonergic function will be determined by measuring ability of tryptophan, a 5-HT precursor, to increase prolactin levels and alter mood. These studies should provide data relevant to the evidence that increased NA function occurs in some forms of human anxiety and some antipanic drugs reduce NA activity. It will evaluate hypothesis, generated from preclinical investigations, that BZ-GABA and 5-HT dysfunction are also related to anxiety development and treatment. The information obtained from these studies may be important for the identification and development of more specific and efficacious treatment for patients with anxiety disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH040140-05
Application #
3378141
Study Section
Treatment Development and Assessment Research Review Committee (TDA)
Project Start
1985-09-01
Project End
1993-01-31
Budget Start
1991-02-01
Budget End
1992-01-31
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Goddard, A W; Woods, S W; Money, R et al. (1999) Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 85:225-40
Southwick, S M; Krystal, J H; Bremner, J D et al. (1997) Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54:749-58
Morgan 3rd, C A; Grillon, C; Southwick, S M et al. (1995) Fear-potentiated startle in posttraumatic stress disorder. Biol Psychiatry 38:378-85
Goddard, A W; Charney, D S; Germine, M et al. (1995) Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry 38:74-85
Germine, M; Goddard, A W; Sholomskas, D E et al. (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54:115-33
Goddard, A W; Sholomskas, D E; Walton, K E et al. (1994) Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36:775-7
Grillon, C; Ameli, R; Merikangas, K et al. (1993) Measuring the time course of anticipatory anxiety using the fear-potentiated startle reflex. Psychophysiology 30:340-6
Goddard, A W; Woods, S W; Sholomskas, D E et al. (1993) Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 48:119-33
Woods, S W; Nagy, L M; Koleszar, A S et al. (1992) Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 12:32-8
Woods, S W; Seibyl, J P; Goddard, A W et al. (1992) Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects. Psychiatry Res 45:67-77

Showing the most recent 10 out of 20 publications